Clinical-stage biopharmaceutical company BeiGene has commenced its Phase I clinical trial of BGB-A317 in China to treat advanced solid tumours.

BGB-A317 is a humanised monoclonal antibody belonging to a class of immuno-oncology agents known as immune checkpoint inhibitors.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It specifically fuses with cell surface receptor PD-1, which is considered to play an important role in downregulating the immune system by inhibiting activation of T-cells.

Unlike the currently approved PD-1 antibodies, BGB-A317 can bind with Fc gamma receptor I specifically engineered out.

The Phase I, open-label, multi-centre study of BGB-A317 has been designed to determine the safety, tolerability, preliminary anti-tumour activity and pharmacokinetics profile of BGB-A317 while treating patients with advanced solid tumours in China.

See Also:

"We are committed to developing BGB-A317 for patients in China, where this exciting class of immuno-oncology agents is still not approved."

Beigene founder and CEO John Oyler said: “We are pleased to report that BGB-A317 is now in Phase I clinical evaluation in mainland China.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“To date, all four of our clinical-stage molecules are active in the clinic in China. We are enthusiastic about the agent’s therapeutic potential, with promising data from an ongoing Phase I study of BGB-A317 in Australia, New Zealand, the US, and Taiwan recently reported at the 2016 Society for Immunotherapy of Cancer Annual Meeting.

“We are committed to developing BGB-A317 for patients in China, where this exciting class of immuno-oncology agents is still not approved.”

The trial will be headed by Professor Yilong Wu from Guangdong General Hospital, while Professor Lin Shen and Professor Jun Guo from Beijing Cancer Hospital will serve as the co-lead investigators.